202 related articles for article (PubMed ID: 22525366)
21. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.
Maekawa T; Mori S; Sasaki Y; Miyajima T; Azuma S; Ohta E; Obata F
Mol Neurodegener; 2012 Apr; 7():15. PubMed ID: 22534020
[TBL] [Abstract][Full Text] [Related]
22. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease.
Lu CS; Simons EJ; Wu-Chou YH; Fonzo AD; Chang HC; Chen RS; Weng YH; Rohé CF; Breedveld GJ; Hattori N; Gasser T; Oostra BA; Bonifati V
Parkinsonism Relat Disord; 2005 Dec; 11(8):521-2. PubMed ID: 16256409
[No Abstract] [Full Text] [Related]
23. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2.
Martí-Massó JF; Ruiz-Martínez J; Bolaño MJ; Ruiz I; Gorostidi A; Moreno F; Ferrer I; López de Munain A
Mov Disord; 2009 Oct; 24(13):1998-2001. PubMed ID: 19735093
[TBL] [Abstract][Full Text] [Related]
24. The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: possible significance in the transgenic model mouse of Parkinson's disease.
Miyajima T; Ohta E; Kawada H; Maekawa T; Obata F
Neurosci Lett; 2015 Feb; 588():142-6. PubMed ID: 25562633
[TBL] [Abstract][Full Text] [Related]
25. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
[TBL] [Abstract][Full Text] [Related]
26. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family.
Funayama M; Hasegawa K; Ohta E; Kawashima N; Komiyama M; Kowa H; Tsuji S; Obata F
Ann Neurol; 2005 Jun; 57(6):918-21. PubMed ID: 15880653
[TBL] [Abstract][Full Text] [Related]
27. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
[TBL] [Abstract][Full Text] [Related]
28. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation.
Wider C; Dickson DW; Wszolek ZK
Neurodegener Dis; 2010; 7(1-3):175-9. PubMed ID: 20197701
[TBL] [Abstract][Full Text] [Related]
29. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations.
Ohta E; Kawakami F; Kubo M; Obata F
FEBS Lett; 2011 Jul; 585(14):2165-70. PubMed ID: 21658387
[TBL] [Abstract][Full Text] [Related]
30. LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?
Taylor JP; Mata IF; Farrer MJ
Trends Mol Med; 2006 Feb; 12(2):76-82. PubMed ID: 16406842
[TBL] [Abstract][Full Text] [Related]
31. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
[TBL] [Abstract][Full Text] [Related]
33. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
Gillardon F
J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
[TBL] [Abstract][Full Text] [Related]
34. Clinical heterogeneity of the LRRK2 G2019S mutation.
Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
[TBL] [Abstract][Full Text] [Related]
35. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
[TBL] [Abstract][Full Text] [Related]
36. LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?
Outeiro TF; Harvey K; Dominguez-Meijide A; Gerhardt E
Biochem Soc Trans; 2019 Jun; 47(3):827-838. PubMed ID: 31085616
[TBL] [Abstract][Full Text] [Related]
37. Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families.
Ohta E; Hasegawa K; Gasser T; Obata F
Neurosci Lett; 2007 Apr; 417(1):21-3. PubMed ID: 17395370
[TBL] [Abstract][Full Text] [Related]
38. Generation of gene-corrected iPSCs line (KEIUi001-A) from a PARK8 patient iPSCs with familial Parkinson's disease carrying the I2020T mutation in LRRK2.
Ohta E; Sone T; Ukai H; Hisamatsu T; Kitagawa T; Ishikawa M; Nagai M; Ueda HR; Obata F; Okano H
Stem Cell Res; 2020 Dec; 49():102073. PubMed ID: 33181472
[TBL] [Abstract][Full Text] [Related]
39. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.
Nguyen APT; Daniel G; Valdés P; Islam MS; Schneider BL; Moore DJ
Hum Mol Genet; 2018 Jan; 27(1):120-134. PubMed ID: 29088368
[TBL] [Abstract][Full Text] [Related]
40. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease.
Haubenberger D; Bonelli S; Hotzy C; Leitner P; Lichtner P; Samal D; Katzenschlager R; Djamshidian A; Brücke T; Steffelbauer M; Bancher C; Grossmann J; Ransmayr G; Strom TM; Meitinger T; Gasser T; Auff E; Zimprich A
Mov Disord; 2007 Aug; 22(11):1640-3. PubMed ID: 17523199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
